---
$id: https://graph.org.ai/products/commodity/51111716
$type: Product
source: UNSPSC
code: "51111716"
title: "Rituximab"
class: "51111700"
classTitle: "Antineoplastic antibiotics"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Rituximab

**UNSPSC Code**: 51111716
**Class**: [Antineoplastic antibiotics](Antineoplastic antibiotics.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody with the molecular formula C6416H9874N1688O1987S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F4X42SYQ6, more generally known as rituximab. European Medicines Agency schedules rituximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12570MIG. The term RITUXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 1 1998, list 39. Most nations schedule rituximab under HS 30021091 and SITC 54163. As of Q4 2014, RITUXIMAB remains the US FDA Preferred Term for this commodity. Rituximab bears US NLM identifiers UMLS ID C0732355 and NCI Concept Code C1702. SMILES: CC(=O)NC1C(C(C(OC1N)CO)O)O.

